Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A bivalent nanoparticle vaccine exhibits potent cross-protection against the variants of SARS-CoV-2

22 Dec 2021

Abstract excerpt

Inoculation against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is ongoing worldwide. However, the emergence of SARS-CoV-2 variants could cause immune evasion. We developed a bivalent nanoparticle vaccine that displays the receptor binding domains (RBDs) of the D614G and B.1.351 strains. With a prime-boost or a single-dose strategy, this vaccine elicits a robust neutralizing antibody and full...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to COVID-19 Clinical Research Studies
Share to SARS-CoV-2 and COVID-19 Research
Share to SARS-CoV-2 detection and testing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34990583
DOI: 10.1016/j.celrep.2021.110256

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A bivalent nanoparticle vaccine exhibits potent cross-protection against the variants of SARS-CoV-2PMID 34990583Read ↗

Challenges and developments in universal vaccine design against SARS-CoV-2 variantsSemantic proximity Read ↗

Immunogenicity and protection of a variant nanoparticle vaccine that confers broad neutralization against SARS-CoV-2 variantsSemantic proximity Read ↗

Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaquesSemantic proximity Read ↗

Universal protection against SARS-CoV-2 viruses by multivalent mRNA vaccine in miceSemantic proximity Read ↗

Nucleic acid delivery of immune-focused SARS-CoV-2 nanoparticles drive rapid and potent immunogenicity capable of single-dose protectionSemantic proximity Read ↗

Immunogenicity and In vivo protection of a variant nanoparticle vaccine that confers broad protection against emerging SARS-CoV-2 variantsSemantic proximity Read ↗

Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccinesSemantic proximity Read ↗

A bivalent recombinant vaccine targeting the S1 protein induces neutralizing antibodies against both SARS‐CoV‐2 variants and wild‐type of the virusSemantic proximity Read ↗

Phylogeny-driven design of broadly protective sarbecovirus receptor-binding domain nanoparticle vaccinesSemantic proximity Read ↗

Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2Semantic proximity Read ↗

Two-Component Nanoparticle Vaccine Displaying Glycosylated Spike S1 Domain Induces Neutralizing Antibody Response against SARS-CoV-2 VariantsSemantic proximity Read ↗

Engineered Multivalent Nanobodies Potently and Broadly Neutralize SARS‐CoV‐2 VariantsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.